Overview
My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.
Current Appointments & Affiliations
Recent Publications
Advancing physician-scientist career development in obstetrics and gynecology: 40 years of the American Association of Obstetricians and Gynecologists Foundation scholar program.
Journal Article Am J Obstet Gynecol · July 23, 2025 Full text Link to item CiteExpanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.
Journal Article Int J Gynecol Cancer · June 21, 2025 OBJECTIVE: Training and supporting early-career investigators are essential for developing a resilient and competent clinical research workforce in gynecologic oncology. To address persistent gaps in mentorship, protected time, funding, and leadership path ... Full text Link to item CiteGenomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.
Journal Article Int J Gynecol Cancer · May 2025 OBJECTIVE: Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought to confirm the proportion of patients with at least 1 actionable a ... Full text Link to item CiteRecent Grants
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a DH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2025 - 2030Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2030Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
Clinical TrialPrincipal Investigator · Awarded by TORL BioTherapeutics, LLC · 2025 - 2030View All Grants